LivingGLP1
Study S002829

A First Human Dose Trial Investigating the Safety, Tolerability and Pharmacokinetics of Single Doses of Oral NNC0113-2023 in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration
NCT03617081
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
40
Start
2018-08-09
Primary completion
2018-12-13
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:NNC0113-2023; DRUG:Placebo (NNC0113-2023)
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1209-3837

Registered primary outcomes

  • Number of treatment emergent adverse events (TEAEs) [From time of dosing (day 1) until completion of the follow-up visit (day 43)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.